Reduction of adiponectin levels in liver tissue of NAFLD patients has been suggested to modulate a pro-inflammatory microenvironment, resulting in increased lipotoxicity and promotion of simple steatosis to NASH and fibrosis (118). The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.